Altimmune (ALT) Research & Development (2010 - 2026)

Altimmune (ALT) has 17 years of Research & Development data on file, last reported at $16.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 2.31% year-over-year to $16.2 million in Q1 2026; TTM through Mar 2026 was $66.8 million, a 12.76% decrease from a year earlier, with the FY2025 full-year figure at $66.4 million, down 19.21% from the prior year.
• Research & Development for Q1 2026 stood at $16.2 million, down from $18.4 million in the prior quarter.
• Over the last five years, Research & Development for ALT reached as high as $21.5 million in Q1 2024 and fell as low as $13.3 million in Q2 2023.
• Historically, Research & Development has averaged $17.7 million across 5 years, with a median of $17.2 million in 2023.
• Across the five-year window, Research & Development plunged 30.62% in 2022 and soared 59.62% in 2024, its largest moves.
• Year by year, Research & Development stood at $19.2 million in 2022, then retreated by 11.84% to $16.9 million in 2023, then climbed by 16.99% to $19.8 million in 2024, then dropped by 6.94% to $18.4 million in 2025, then decreased by 12.04% to $16.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $16.2 million in Q1 2026, $18.4 million in Q4 2025, and $15.0 million in Q3 2025.